Reagent Validation to Facilitate Experimental Reproducibility
- PMID: 29927084
- DOI: 10.1002/cpph.40
Reagent Validation to Facilitate Experimental Reproducibility
Abstract
Many results reported in the biomedical research literature cannot be independently reproduced, undermining the basic foundations of science. This overview is intended for researchers who are committed to improving the quality and integrity of biomedical science by raising awareness of both the sources of irreproducibility, and activities specifically targeted to address the issue. The irreproducibility of biomedical research is due to a variety of factors, known and unknown, that markedly influence experimental outcomes. Among the known factors are inadequate training or mentoring, or experimenter incompetence. These may result in flawed experimental design and execution that reflect a lack of planning, leading to an underpowering of a study, an absence of appropriate controls, selective data analysis, inappropriate statistical analysis, and/or investigator bias or fraud. Another frequently overlooked source of irreproducibility is failure to ensure that the equipment used is performing up to manufacturer specifications. Failure to validate/authenticate the experimental reagents is another source of irreproducibility. These include compounds, cell lines, antibodies, and the animal models used in a study. This overview discusses how a lack of validation of research reagents negatively impact experimental reproducibility, and provides guidelines to avoid these pitfalls. © 2018 by John Wiley & Sons, Inc.
Keywords: antibodies; cell lines; compounds; validation.
© 2018 John Wiley & Sons, Inc.
Similar articles
-
Unknown unknowns in biomedical research: does an inability to deal with ambiguity contribute to issues of irreproducibility?Biochem Pharmacol. 2015 Sep 15;97(2):133-6. doi: 10.1016/j.bcp.2015.07.002. Epub 2015 Jul 31. Biochem Pharmacol. 2015. PMID: 26239804 Review.
-
Logical Experimental Design and Execution in the Biomedical Sciences.Curr Protoc Pharmacol. 2017 Mar 17;76:A.3G.1-A.3G.26. doi: 10.1002/cpph.20. Curr Protoc Pharmacol. 2017. PMID: 28306153
-
Guidelines for manuscript submission in the peer-reviewed pharmacological literature.Biochem Pharmacol. 2015 Oct 1;97(3):225-35. doi: 10.1016/j.bcp.2015.06.023. Epub 2015 Jul 21. Biochem Pharmacol. 2015. PMID: 26208784
-
Irreproducibility in Preclinical Biomedical Research: Perceptions, Uncertainties, and Knowledge Gaps.Trends Pharmacol Sci. 2016 Apr;37(4):290-302. doi: 10.1016/j.tips.2015.12.001. Epub 2016 Jan 6. Trends Pharmacol Sci. 2016. PMID: 26776451 Review.
-
The increasing urgency for standards in basic biologic research.Cancer Res. 2014 Aug 1;74(15):4024-9. doi: 10.1158/0008-5472.CAN-14-0925. Epub 2014 Jul 17. Cancer Res. 2014. PMID: 25035389 Free PMC article.
Cited by
-
Workshop on reproducibility in research.J Clin Transl Sci. 2020 Jun 19;4(6):562-564. doi: 10.1017/cts.2020.496. J Clin Transl Sci. 2020. PMID: 33948232 Free PMC article.
-
Improving target assessment in biomedical research: the GOT-IT recommendations.Nat Rev Drug Discov. 2021 Jan;20(1):64-81. doi: 10.1038/s41573-020-0087-3. Epub 2020 Nov 16. Nat Rev Drug Discov. 2021. PMID: 33199880 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources